High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Fixed-rate bonds cannot outrun inflation over a 25-year retirement, yet most boomers keep reaching for them anyway. Three companies have raised their dividends for between 50 and 70 consecutive years and may offer a more durable solution, though each carries a hidden transition risk that income investors need to weigh.
On Tuesday’s episode of CNBC’s Mad Money, Jim Cramer highlighted Kimberly-Clark Corporation (NYSE:KMB) as a defensive holding for investors looking to lock in profits from high-flying technology stocks and reallocate into lower-risk value plays. After years of sluggish price action, Cramer noted that the consumer giant has finally established a stable bottom, anchored by a […]
Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.
J&J’s Ottava clearance knocked Intuitive's shares lower, but recurring revenue and surgeon switching costs suggest the market overreacted.
Johnson & Johnson's Q2 beat and strong pharma momentum are raising interest in healthcare ETFs with sizable exposure to the company.
Earlier this week, Johnson & Johnson announced that the FDA had granted De Novo authorization for its OTTAVA Robotic Surgical System, a table‑integrated soft tissue platform cleared for a range of general surgery procedures including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy and appendectomy. This authorization makes Johnson & Johnson a new competitor in U.S. soft‑tissue robotic surgery, potentially reshaping procedure choices for hospitals and surgeons that have long relied on...
Generic drugmakers have much thinner margins, and are less interested in “reshoring” to the US where the costs are higher.
Investors reacted to enterprise spending delays, healthcare competition, and weakening consumer demand.
Intuitive Surgical stock sinks as FDA announces marketing authorization for Johnson & Johnson’s Ottava platform. Here’s why the news is largely bearish for ISRG shares.
While not disclosing a specific launch timeframe, with de novo clearance in hand, J&J initially plans to launch Ottava with “select customers”.
Intuitive Surgical's growth rests on da Vinci 5, Ion, SP and digital tools as recurring revenue rises and procedure risks persist.
ISRG's growth is fueled by robotic surgery, Ion lung biopsy and AI tools, while tariffs, product mix and softer demand pressure margins.
ISRG's strong procedure growth, recurring revenue and cash position support its case, but tariffs, mix shifts and placement risks cloud the outlook.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
By Puyaan Singh July 22 (Reuters) - Johnson & Johnson said on Wednesday the U.S.
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Liquidia's Yutrepia is driving strong growth with rapid commercial adoption as the company expands its pipeline and competes in the evolving PAH market.
While Johnson & Johnson will go head to head with Intuitive in the U.S., analysts questioned whether its robotic surgery system will take meaningful share from the market leader.
Johnson & Johnson (JNJ) has declared a third quarter 2026 cash dividend of $1.34 per share, providing income focused investors with fresh information on the stock’s current payout profile and upcoming key dates. See our latest analysis for Johnson & Johnson. The latest dividend announcement comes shortly after Johnson & Johnson reported second quarter 2026 results, raised full year sales guidance to US$100.8b to US$101.4b, and secured FDA approval for its dual energy THERMOCOOL SMARTTOUCH SF...
The market is offering a steep discount on this medical device maker, but the price tag comes with a story about slowing growth. Here’s how to read it.
At $353, Intuitive Surgical (ISRG) is being priced to deliver 14.1% revenue growth annually for the next 4 years simply to defend today's 42.1x multiple. That sits below the 21% the business is currently growing at, which is the unusual part. The multiple has already priced in a slowdown that has not yet appeared.
JNJ is pruning its portfolio while Abbott just dropped $21 billion to expand into cancer diagnostics, and the two strategies are pulling their stocks in completely opposite directions. Which move looks smarter when you dig into the actual earnings?
Halozyme grants ENHANZE rights to Incyte for developing subcutaneous cancer therapy formulations, aiming to improve treatment convenience for patients.
Seventy companies have raised their dividends through every recession and rate shock for at least a quarter century, but a bruising few quarters for some of NOBL's most-watched names put that unbroken record under real pressure heading into mid-2026.
Johnson & Johnson, Lam Research and Seagate lead today's analyst picks as strong results, AI demand and growth outlooks drive the latest research.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
